Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
Eligible age
18–75 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease worldwide and predominately affects individuals with overweight and obesity, as well as those with type 2 diabetes and cardiovascular disease. Tirzepatide is a medication used to treat type 2 diabetes and obesity. It has also been shown to help with MASLD. The purpose of this study is to study how tirzepatide affects the liver in patients with MASLD. Participants will be asked to: * Take tirzepatide for 12 months. * Come in for clinic visits every 3 months. * Have blood drawn at baseline, 6, and 12 months. * Complete a liver ultrasound at baseline and at 12 months.
Sponsor: University of New Mexico
You may qualify if…
- ✓ Men and women
- ✓ Age 18-75
- ✓ Diagnosis of MASLD based on the following criteria:
- ✓ Presence of at least 1 out of the 5 following cardiometabolic criteria:
- ✓ BMI \>25 kg/m2 OR waist circumference \>94 cm (men) or 80cm (women)
- ✓ Fasting serum glucose \>100 mg/dL OR 2-hour post-prandial glucose levels \>140mg/dL OR AbA1c \>5.7% OR type 2 diabetes OR treatment for type 2 diabetes
- ✓ Blood pressure \>130/85 mmHg OR specific antihypertensive drug treatment
- ✓ Plasma triglycerides \>150mg/dL OR on lipid lowering treatment
You may not qualify if…
- ✕ Pregnancy or breast feeding
- ✕ Premenopausal women not on any form of contraception
- ✕ Reports alcohol intake \>50g/day or 350g/week for women and \>60g/day or 420g/week for men or an AUDIT score \>8
- ✕ Other identifiable causes of steatosis
- ✕ Documented allergic reaction to tirzepatide or any other GLP1 RA
- ✕ Decompensated liver disease
- ✕ Decompensated renal disease requiring hemodialysis
- ✕ Decompensated heart failure
Where it's recruiting
Albuquerque
Source: ClinicalTrials.gov · NCT06934642 · last updated 2025-07-14